Latest Merrimack Pharmaceuticals Inc. Stories
CAMBRIDGE, Mass., April 28, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
Updated clinical data presented in an oral session at the 2015 American Association for Cancer Research Annual Meeting CAMBRIDGE, Mass., April 21, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals,
Median progression-free survival of 7.6 months reported for overall study population whose disease has progressed on a median of 4 prior therapies CAMBRIDGE, Mass., April 20, 2015 /PRNewswire/
Phase 1 study of MM-302 will be presented in a plenary oral session CAMBRIDGE, Mass., March 26, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
HAYWARD, California, March 9, 2015 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc.
MM-398 in Combination with 5-FU and Leucovorin Provides New Treatment Option for Patients Previously Treated with Gemcitabine MANHATTAN BEACH, Calif., May 1, 2014 /PRNewswire/ --
- Emitting flashes of light; glittering.